

# Hypomethylation of the *Synuclein* $\gamma$ Gene CpG Island Promotes Its Aberrant Expression in Breast Carcinoma and Ovarian Carcinoma<sup>1</sup>

Anu Gupta, Andrew K. Godwin, Lisa Vanderveer, AiPing Lu, and Jingwen Liu<sup>2</sup>

Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304 [A. G., A. L., J. L.], and Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [A. K. G., L.V.]

## ABSTRACT

Recent studies indicate that *synuclein*  $\gamma$  (*SNCG*) gene, located in chromosome 10, participates in the pathogenesis of the breast and ovary. *SNCG*, also known as *breast cancer-specific gene 1* (*BCSG1*), is not expressed in normal mammary or ovarian surface epithelial cells but is highly expressed in the vast majority of advanced staged breast and ovarian carcinomas. When overexpressed, *SNCG* significantly stimulates breast cancer proliferation and metastasis. To fully understand the molecular mechanisms underlying the abnormal expression of *SNCG* in neoplastic diseases, in this study, we extensively examined the methylation status of a CpG island located in exon 1 of *SNCG* gene in a panel of breast and ovarian tumor-derived cell lines to determine whether DNA methylation plays a crucial role in *SNCG* expression. *In vivo* bisulfite DNA sequencing of genomic DNA isolated from breast cancer cell lines showed that the 15 CpG sites within the CpG island were completely unmethylated in all *SNCG*-positive cell lines (5 of 5), but were densely and heterogeneously methylated in the majority of *SNCG*-negative cell lines (3 of 4). The methylation occurred primarily at the CpG sites 2, 5, 7, and 10–15. Similarly, we observed a strong correlation of hypomethylation of the CpG island and *SNCG* expression in ovarian cancer cell lines (5 of 5). Intriguingly, the methylation pattern in ovarian cancer cells is different from that in breast cancer cells. In *SNCG*-nonexpressing ovarian cancer cells, all 15 of the CpG sites were completely methylated instead of selective methylation at certain sites shown in breast cancer cells, thereby suggesting a tissue-specific methylation pattern. A correlation between hypomethylation of the exon 1 and expression of *SNCG* mRNA was also observed in primary breast tumor tissues. The importance of DNA methylation in the control of *SNCG* expression in cancer cells is further strengthened by demonstration of re-expression of *SNCG* mRNA in *SNCG*-negative ovarian and breast cancer cells with a demethylating agent 5-aza-2'-deoxycytidine. In addition, we demonstrate that inhibition of cell growth leads to a decreased mRNA expression and an increased DNA methylation of *SNCG* gene. Taken together, these new findings strongly suggest that DNA hypomethylation is a common mechanism underlying the abnormal expression of this candidate oncogene in breast and ovarian carcinomas.

## INTRODUCTION

Recently, methylation of DNA at CpG dinucleotides has been recognized as an important mechanism for regulation of gene expression in mammalian cells. Methylation of cytosines in the CpG sequence located in the promoter region or exon 1 is thought to ensure the silencing of certain tissue-specific genes in nonexpressing cells. Aberrant methylation is now considered an important epigenetic alteration occurring in human cancer. Hypermethylation of normally

unmethylated tumor suppressor genes correlates with a loss of expression in cancer cell lines and primary tumors (1–4). On the other hand, failure to repress genes appropriately by abnormal demethylation of tissue-restricted genes or by hypomethylation of proto-oncogenes could result in the loss of tissue specificity and could promote cancer formation (5, 6). Numerous investigations suggest that hypermethylation of promoter CpG islands correlates with transcriptional inhibition in neoplasms. Most of the hypermethylated CpG islands are located in the promoter region of tumor suppressor genes or DNA repair genes, and DNA methylation is associated with the loss of gene expression in cancer cell lines and primary tumors. However, compared with an extensive list of tumor suppressor genes or cell cycle-regulated genes that are silenced in cancer cells to date, only a few genes have been shown transcriptionally reactivated by DNA demethylation in cancer (7). Although the global hypomethylation in cancers has been observed for several years, it has not received much attention until recently. Initially, hypomethylation of human growth hormone,  $\alpha$ -globin, and  $\gamma$ -globin in cancers was observed by Feinberg and Vogelstein (8). These genes are methylated in normal tissues and become hypomethylated in cancers. Later on, the study was extended to various grades of tumors like benign and malignant colon neoplasms, and hypomethylation was observed in both types of tumors (9). The hypomethylation and overexpression of proto-oncogenes *c-Myc* and *c-Jun* has been detected in chemically induced tumors in mouse liver (10). Rosty *et al.* (11) has recently reported hypomethylation of *S100A4* gene in pancreatic cell carcinomas. A correlation of hypomethylation and expression of MN/CA9 (a tumor-associated antigen) was reported by Cho *et al.* (12) in renal cell carcinomas. Additionally, DNA hypomethylation and overexpression has been shown for *MDR* in myeloid leukemias (13), *BCL-2* in chronic lymphocytic leukemias (14), *MAGE-1* in melanomas (15), and c-Ha-RAS in gastric carcinomas (10). Recently, Strichman-Almashanu *et al.* (16) have identified unique CpG islands that are methylated specifically in normal tissues and not in cancers.

*SNCG*,<sup>3</sup> also referred to as the *BCSG1* (*breast cancer specific gene 1*), is a member of a neuronal protein family synuclein and its expression is highly tissue specific (17–21). The *SNCG* protein is abundantly expressed in the peripheral nervous system such as primary sensory neurons, sympathetic neurons, and motor neurons. However, this tissue specificity was apparently lost during the disease progression of breast cancer and ovarian cancer, because this gene, normally silent in breast tissue and ovary, became abundantly expressed in the vast majority of the advanced staged breast carcinoma and ovarian carcinoma.

The involvement of *SNCG* in human neoplastic diseases first came to light 5 years ago when *SNCG* was isolated from a human breast tumor cDNA library and was shown to be overly expressed in infiltrating ductal carcinomas (22). By using *in situ* hybridization, Jia *et al.* demonstrated a stage-specific expression pattern of *SNCG* mRNA, varying from virtually no detectable expression in normal or benign

Received 4/18/02; accepted 11/26/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> Supported by the Department of Veterans Affairs (Office of Research and Development, Medical Research Service), by a grant from the Ovarian Cancer Research Fund (to A. K. G.), by Grants 1RO1CA83648-01 (to J. L.) and Specialized Programs of Research Excellence (SPORE) P50 CA83638 (to A. K. G.) from National Cancer Institute, and by a Grant (BC010046) from the United States Army Medical Research and Materiel Command (to J. L.).

<sup>2</sup> To whom requests for reprints should be addressed, at (154P), VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304. Phone: (650) 493-5000, extension 64411; Fax: (650) 849-0251; E-mail: Jingwen.Liu@med.va.gov.

<sup>3</sup> The abbreviations used are: *SNCG*, synuclein  $\gamma$ ; 5-Aza-C, 5-aza-2'-deoxycytidine; FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HMEC, human mammary epithelial cell; MSP, methylation-specific PCR; OM, oncostat M; RT, reverse transcription.

breast tissues to low level and partial expression in low-grade ductal carcinoma *in situ* (DCIS) to high expression in advanced infiltrating carcinomas. Immunohistochemical studies to examine SNCG protein expression showed a similar pattern in that it was not detected in normal breast tissues but was detected in a high percentage of stage III/IV breast ductal carcinomas (23). SNCG expression in advanced breast carcinomas is not merely adventitious, but plays a positive role in the process of invasion and metastasis. Our groups and others have demonstrated that exogenous expressions of SNCG induced a more aggressive and invasive phenotype in the breast cancer cell line MDA-MB435 (24), and the inhibition of SNCG with SNCG antisense mRNA reversed the malignant phenotypes of T47D cells (25).

The first piece of evidence suggesting a possible role of SNCG in the development of ovarian carcinoma came from an analysis of the expressed sequence tag database. Lavedan *et al.* (20) noticed that 37% of the human SNCG sequences were originated from an ovarian tumor library, and the rest of the sequences were from brain and breast tumor libraries, thereby predicting that SNCG may also be overexpressed in ovarian tumor. This speculation was confirmed later by Bruening *et al.* (23), who conducted a study to examine SNCG expression in normal ovarian tissue samples and tissues from ovarian carcinoma. This study found that ovarian epithelial cells or ovarian stromal cells from normal ovaries were not stained with anti-SNCG antibody. In contrast, Bruening *et al.* showed that 33 (73%) of 45 ovarian carcinomas strongly reacted with anti-SNCG antibody, and the immunoreactivity was exclusively in malignant ovarian epithelial cells.

To elucidate the mechanisms that underlie the abnormal expression of SNCG in breast cancer cells, a 2.2 kb-fragment of human *SNCG* gene including 1 kb of the 5'-flanking region (-1260 to -170), exon 1 (-169 to +121), and intron 1 (+122 to +935), was isolated in the VA Palo Alto laboratory (26). Our previous studies of SNCG promoter activity in two SNCG-positive and one SNCG-negative breast cancer cell lines suggested that SNCG transcription is primarily controlled by regulatory sequences located in intron 1 and exon 1 but not in the 5' flanking region.

The intron 1 contains two closely located AP1 recognition sequences. Deletion of these motifs greatly diminished the SNCG promoter activity, suggesting that AP1 is an important transactivator for SNCG transcription in breast cancer cells. Sequence analysis identified a CpG island in exon 1 that contains 15 CpG sites, covering the region -169 to +81, relative to the translation start codon. By using the sodium bisulfite DNA sequencing technique that examined the *in vivo* methylation pattern of the exon 1 region, we found that the CpG sites within the CpG island and its vicinity were partially and heterogeneously methylated in SNCG-negative MCF-7 cells but unmethylated in SNCG-positive SKBR-3 and T47D cells (26).

These initial observations suggest that demethylation of SNCG exon 1 could play a causative role for the expression of SNCG in cell culture. To determine whether demethylation of the exon 1 is a common molecular determinant responsible for the abnormal expression of SNCG in breast carcinoma and ovarian carcinoma, in the present study, we extensively examined the methylation status of exon 1 and SNCG expression in a panel of breast cancer and ovarian cancer cell lines, and in primary breast tumor and normal breast tissues.

## Materials and Methods

**Cells and Culture Conditions.** The breast cancer cell lines, AU565, MCF-7, MDA-MB435, MDA-MB231, MDA-MB 468, T47D, SKBR-3, were cultured in RPMI 1640 with 10% FBS. H3922 was grown in Iscove's modified Dulbecco's medium in the presence of 10% FBS and BT-20 was grown in DME H-16 50% and F-12 50% media supplemented with 10% FBS. The normal mammary epithelial-derived cell line MCF10A was obtained from

American Type Culture Collection (ATCC) and cultured according to the instruction provided by ATCC. Two normal human primary mammary epithelial cell lines 184 and 048R with finite life span were cultured in 1:1 mixture of DME/F-12 supplemented with 0.5% FBS, 10  $\mu$ g/ml insulin, 5 ng/ml epidermal growth factor, 0.1  $\mu$ g/ml hydrocortisone, and 1 ng/ml cholera toxin. The third finite life span primary cell line derived from the organoid 240L was cultured in complete MEGM medium (Clonetics) supplemented with  $10^{-5}$  M isoproterenol. All HMECs and organoids, and the organoid-derived cell line (240L) were kindly provided by Dr. Martha R. Stampfer at the Lawrence Berkeley National Laboratory, in Berkeley, CA.

The ovarian carcinoma-derived cell lines (A2780 and OVCAR-3, -4, -5, -8) were maintained in DMEM supplemented with 10% FBS, glutamine, and insulin (0.2 IU/ml pork insulin; Novagen; Ref. 27). Human ovarian surface epithelial cell lines were derived as described previously (28). Cells were maintained in a 1:1 mixture of Media 199 and MCDB-105 media, supplemented with 4% FBS and 0.2 IU/ml insulin (29). The life spans of the human ovarian surface epithelial cells (HIO-103, -105, -107, -135) have been extended by ectopically expressing SV40 large T-antigen. These cell lines are nontumorigenic with the exception of HIO-118, which has been shown to form tumors in mice.<sup>4</sup>

**Isolation of Genomic DNA from Cell Lines and Tissues.** The genomic DNA was isolated from various cell lines by using Promega's wizard DNA isolation kit according to the manufacturer's instructions. Primary breast tumor tissues and normal breast tissues were obtained after surgical resection and stored frozen at  $-80^{\circ}$  C. The tissues were incubated at  $55^{\circ}$  C in homogenization buffer containing 50 mM Tris (pH 8.0), 1 mM EDTA, 0.5% Tween 20, and 5 mg/ml proteinase K for 3 h, and then genomic DNA was isolated using Promega's DNA isolation kit. Donors of tissue specimens agreed to allow their specimens to be used for research purposes. Breast tumors were staged following standard American Joint Committee on Carcinoma/International Union Against Carcinoma tumor-node-metastasis (TNM) methodology.

**Genomic Bisulfite DNA Sequencing.** Two  $\mu$ g of genomic DNA from each sample was modified by sodium bisulfite as described previously (2). The modified DNA was amplified with primer SNCG-S2F and SNCG-S2R covering the region -275 to +140. PCR reactions were performed in a volume of 50  $\mu$ l containing 1 $\times$  PCR buffer, 1.5 mM  $MgCl_2$ , 0.2 mM dNTP, 25 pM of each primer, and 2.5 units of platinum Taq polymerase (Life Technology Inc.). PCR reaction was carried out at  $94^{\circ}$  C for 1 min, and 35 cycles at  $94^{\circ}$  C for 30 s,  $55^{\circ}$  C for 30 s, and  $72^{\circ}$  C for 30 s, and finally  $72^{\circ}$  C for 5 min. The 415-bp PCR product was gel purified and ligated into PCR2.1 Topo cloning vector (Invitrogen, Carlsbad, CA). After transformation, individual colonies were picked, and the insert was PCR amplified as described above and sequenced using SNCG-S2R as the primer. Table 1 provide the sequences of the oligonucleotide primers used in this study.

**RT-PCR Analysis of SNCG mRNA.** For cell lines, Ultraspec RNA reagent (Biotechs Laboratory, Houston, TX) was directly added to the monolayer cell culture grown in culture dishes. For isolation of RNA from tumor tissues, 50–200 mg tissues were homogenized in 2–3 ml of Ultraspec RNA reagent on ice using polytron homogenizer at the setting of 3 with three 10-s bursts. RNA was then isolated from the lysate according to the vendor's protocol. The RT was conducted with random primers (Promega) using Superscript II (Invitrogen). The PCR reaction was carried out at  $94^{\circ}$  C for 30 s,  $60^{\circ}$  C for 30 s, and  $72^{\circ}$  C for 30 s, with initial activation of the enzyme at  $94^{\circ}$  C for 1 min. Thirty-eight cycles were performed for SNCG and 26 cycles for GAPDH. The PCR was performed using primers SNCG-RT 5' and SNCG-RT 3' for SNCG and primers GAPDH-RT 5' and GAPDH-RT 3' for GAPDH.

**Western Blot Analysis.** Total cell lysates were isolated from cells as described previously (30). Fifty  $\mu$ g of protein from total cell lysate per sample was separated on 15% SDS PAGE, transferred to nitrocellulose membranes, blotted with goat anti-SNCG polyclonal antibody (E-20, sc-10698; Santa Cruz Biotechnology) at 1:200 dilution using an enhanced chemiluminescence (ECL) detection system (Amersham). Membranes were stripped and reblotted with anti- $\beta$ -actin monoclonal antibody (Sigma) to normalize the amount of protein loaded on gels.

**MSP.** Two  $\mu$ g of genomic DNA isolated from ovarian cell lines was treated with sodium bisulfite and purified using Promega's DNA clean-up kit.

<sup>4</sup> A. K. Godwin, unpublished observations.

Table 1 Sequences of *SNCG* gene-specific primers

Primer	Nucleotide sequence (5' to 3')
<b>RT-PCR primers</b>	
SNCG-RT 5'	CAAGAAGGGCTTCTCCATCGCCAAGG
SNCG-RT 3'	CCTCTTCTCTTTGGATGCCACACCC
GAPDH-RT 5'	CCATCACTGCCACCCAGAAGAC
GAPDH-RT 3'	GGCAGGTTTTTCTAGACGGCAG
<b>Bisulfite sequencing PCR primers</b>	
SNCG-S2F	GGTTGAGTTAGTAGGAGTTTA
SNCG-S2R	CCTACCATACCCCACTTACCC
<b>MSP primers</b>	
SNCG-U1CF	GGTTTTGTATTAATATTTTATTGGTG
SNCG-U2R	ACAAAATAAATCTCCCTACAACTACAA
SNCG-M1F	TGTTATTAATATTTTATCGGCGT
SNCG-M2R	ACGAACTAAATCTCCCTACGAACTACGT
SNCG-WF	ACGCAGGGCTGGCTGGGCTCCA
SNCG-WR	CCTGCTTGGTCTTTTCCACC

The treated DNA was dissolved in 20  $\mu$ l of water, and 2  $\mu$ l was used for MSP. The primers specific for unmethylated DNA were SNCG-U1CF and SNCG-U2R; the primers for methylated DNA were SNCG-M1F and SNCG-M2R. These two sets of primers were designed to amplify the same region of exon 1 from -139 to -37, covering the CpG sites 2-11 and yielding a product of 102 bp. The PCR conditions for both sets of primers were as follows: first cycle at 94°C for 1 min to activate the hot start enzyme, then 30 cycles of 94°C for 30 s, 52°C for 30 s, and 72°C for 30 s, and a final elongation at 72°C for 5 min.

**5-Aza-C Treatment.** The SNCG-negative breast cancer cell lines (MCF-7 and MDA-MB435) and ovarian cell lines (HIO-135, OVCAR4, and OVCAR8) were cultured in medium containing 0, 1, 5, or 10  $\mu$ M of 5-Aza-C for 6 days. The medium and drug were replaced every 24 h.

**Stable Transfection of MCF-7 Cell Line.** MCF-7 cells were transfected with pCIneo vector alone (mock transfected) or with pCIneo-SNCG, and the pooled transfectants were selected by adding 300  $\mu$ g/ml of G418. The expression of SNCG was confirmed by Western blotting and the cells were further used for proliferation assays.

**Proliferation Assay.** For HMEC-184,  $1.2 \times 10^4$  cells were seeded in 24-well plate and treated with 50 ng/ml of OM for 1 and 3 days. [<sup>3</sup>H]thymidine incorporation was done as described previously (31). For mock- and SNCG-transfected MCF-7 cells,  $1 \times 10^3$  cells were seeded in black 96-well plates in RPMI medium containing 10% FBS and were harvested at indicated intervals of time. The total DNA content was estimated using cyquant cell proliferation assay kit (Molecular Probes) as per the manufacturer's instructions.

**Flow Cytometry Analysis.** MCF7-SNCG or MCF7-neo cells were seeded at a density of  $2 \times 10^5$  in 100-mm dishes in RPMI containing 10% serum. After 24 h, the medium was replaced with RPMI having 0.5% serum. The cells were harvested after 48 h, and DNA content was analyzed as described earlier (32).

**Statistical Analysis.** Comparisons of experimental data were analyzed by a two-tailed Student's *t* test. A *P* < 0.05 was considered to indicate a statistically significant difference.


## RESULTS

**Examination of SNCG mRNA Expression in Malignant and Normal Mammary Epithelial Cell Lines.** Total RNA was isolated from 10 breast cancer cell lines, and RT-PCR was conducted using specific primers for SNCG and a housekeeping gene, *GAPDH*. SNCG mRNA was detected in 6 of 10 cell lines including AU565, BT-20, SKBR-3, T47D, H3922, and MDA-MB231 (Fig. 1A, and data not shown). The remaining four cell lines either showed no expression of SNCG mRNA such as MCF-7, H3396, and MDA-MB435 or expressed this gene at a very low level (Fig. 1A, *MDA-MB468*). In contrast, RT-PCR detected equal expression of *GAPDH* mRNA in all of the cell lines. Western blot analysis (Fig. 1B), using specific anti-SNCG antibody, demonstrated SNCG protein expression in the same six cell lines that express the mRNA but not in the four cell lines that express no mRNA or a trace amount, thereby providing a solid validation for the results of the RT-PCR.

We further examined SNCG mRNA and protein expression in one normal mammary epithelium-derived cell line, MCF10A, and 2 primary normal HMEC lines, HMEC-184 and HMEC-048R. Unlike MCF10A cells that can grow in culture indefinitely, the HMEC lines have limited life span. Fig. 1C shows that MCF10A expressed a trace amount of SNCG mRNA, as detected by RT-PCR, but SNCG protein could not be detected by immunoblotting. Unexpectedly, both of the HMEC cells showed reasonable levels of SNCG mRNA and protein, which contradicted previous studies by *in situ* hybridization and Western blot that neither detected the mRNA or the protein of SNCG using normal human breast tissues, suggesting that culturing *in vitro* may induce *SNCG* gene expression.

**Methylation Status of SNCG Exon 1 in Malignant and Normal Mammary Epithelial Cell Lines.** To identify the correlation between DNA methylation of exon 1 and expression of SNCG, we examined the *in vivo* methylation status of all of the cell lines by genomic bisulfite sequencing. Genomic DNAs were treated with sodium bisulfite, and the modified DNAs were amplified with the primer SNCG-S2F and SNCG-S2R. This primer set specifically amplified the modified sense strand of *SNCG* gene from -275 to +140, covering the entire exon 1 and its vicinity. The results obtained from 12 cell lines are summarized and are shown schematically in Fig. 2.

Fig. 1. SNCG expression in breast cancer cell lines and normal HMEC lines. A, SNCG mRNA expression in 10 breast cancer cell lines was examined by RT-PCR analysis. One  $\mu$ g of total RNA was used in the reaction of RT in a volume of 20  $\mu$ l. Two  $\mu$ l of the RT product was used in PCR with specific primers to SNCG or *GAPDH*. The RT-PCR products were separated on a 1.5% agarose gel and stained with ethidium bromide. B, SNCG protein expression in the same cancer cell lines was examined by Western blot by using 20  $\mu$ g of protein of total cell lysate. C, SNCG expression in two finite life-span HMECs (184 and 048R) and one immortalized HMEC line (MCF10A) was examined by RT-PCR (top panel) and Western blot (bottom panel) as described in A and B.






Fig. 2. Methylation status of CpG island in SNCG exon 1 region in various breast cancer cell lines. Genomic DNA was isolated from different cell lines and was modified by sodium bisulfite. Primers SNCG-S2F and SNCG-S2R were used to amplify the region -275 to +140 of modified sense strand of SNCG. CpG positions are indicated relative to the translation start codon, and each circle in the figure represents a single CpG site. For each cell line, the percentage methylation at a single CpG site is calculated from the sequencing results of 6–8 independent clones. ●, 100% methylation; ○, 0% methylation.

The data demonstrated a specific and consistent pattern of methylation in four of five SNCG-negative cell lines. In MCF10A cells, the CpG sites, 2, 5, 7, and 10–15 CpG, were consistently methylated, a pattern identical to the other three cancer cell lines (MDA-MB435, MDA-MB468, and MCF-7). In contrast to SNCG-negative cells, all SNCG-positive cell lines contain unmethylated exon 1. H3396 is the only cell line that has unmethylated CpG island but did not express the *SNCG* gene. In this cell line, repression of transcription by other factors such as lack of transcriptional activator or expression of repressor, may contribute to the loss of SNCG expression despite promoter demethylation. Nevertheless, the results presented in Figs. 1 and 2 clearly demonstrate that the silencing of SNCG expression in mammary epithelial cell lines is correlated predominantly with methylation of exon 1 at specific CpG sites regardless of whether they were originated from breast tumor or from normal breast tissue.

### Examination of SNCG mRNA Expression and the Status of Exon 1 Methylation in Primary Breast Tumors.

Because the above data confirmed a role of demethylation in *SNCG* gene expression in breast cancer cells in culture, we wanted to know whether the demethylation-dependent gene expression occurs under *in vivo* conditions as well. First, using RT-PCR assays, we examined SNCG mRNA expression in 10 breast tumors, most of which were diagnosed as invasive ductal carcinoma with histological grade of II and above. The pathological characteristics of the tumor samples are listed in Table 2. The expression level of SNCG mRNA in the tumor-adjacent normal tissue from each patient was also determined. In this experiment, T47D cells were used as a positive control. Fig. 3. *top panel*, show the results of RT-PCR and the *next panel down* presents the relative SNCG mRNA levels after normalization with the signal of GAPDH. These results demonstrate that of 10 patient samples, 9 patients displayed SNCG expression in tumor samples. SNCG mRNA was not detected in five tumor-adjacent normal tissues (N1, N5, N7, N8, and N10), whereas low levels were detected in other four normal samples (N2, N3, N6, and N9), and a high level was found in N4. The detection of SNCG expression in the five tissue samples, supposed to be normal, prompted us to reexamine the original tissue slices; we found that all of the adjacent “normal” tissues contained regions of infiltrating tumor cells, which were the likely source of SNCG mRNA detected in these tissue samples.

Second, to determine whether the expression of SNCG in breast tumors is associated with hypomethylation, we selected five patient samples of both tumor and normal tissues for genomic bisulfite sequencing. The sequencing results are summarized in Table 3. The N/T pair number 7, which were SNCG-negative for both the normal tissue and the tumor, showed methylation in five of five clones for normal tissue and four of six clones for tumor. Importantly, the methylation occurred at the CpG sites 2, 5, 7, and 10–15, exactly matching the methylation pattern seen in cell lines. The N/T pair number 8, in which the normal tissue did not show any expression and the tumor showed low level of SNCG mRNA, the exon 1 was methylated in all of the clones from the normal tissue and was partially demethylated in the tumor tissue. In N/T pair number 6, the exon 1 was unmethylated for both normal and tumor tissues, which correlated well with the SNCG expression. In N/T pairs numbers 1 and 5, the exon 1 was unmethylated in tumors as well as in normal tissues, albeit with a lack of SNCG expression in normal tissues, suggesting that demethylation could occur before the gene expression. Taken together, the results from breast tumor tissues agreed to a large extent with the results from breast cancer cell lines and provided critical *in vivo* evidence to support the role of DNA methylation in the control of SNCG expression.

Table 2. Characteristics of surgical breast tumor specimens

The tumors were staged following standard American Joint Committee on Carcinoma/International Union against Carcinoma tumor-node-metastasis methodology. The SNCG mRNA expression was determined by RT-PCR and normalized with the mRNA levels of GAPDH as shown in Fig. 3. The double ++ sign indicates the ratio of SNCG mRNA:GAPDH mRNA > 1, the single + sign indicates a ratio of SNCG mRNA:GAPDH mRNA > 0.25, and the - sign indicates a ratio of SNCG mRNA:GAPDH mRNA < 0.2.

Tumor sample no.	Diagnosis	Histologic grade	Nuclear grade	Tumor cells positive axillary lymph nodes	ER	SNCG mRNA expression
T1	Infiltrating (95%) and <i>in-situ</i> carcinoma	III	na <sup>a</sup>	34/38	na	++
T2	<i>In-situ</i> and invasion duct carcinoma	na	na	11/15	na	++
T3	<i>In-situ</i> and infiltrating duct carcinoma	III	na	15/26	+	+
T4	<i>In-situ</i> and invasion duct carcinoma	III	III	0/22	-	+
T5	<i>In-situ</i> and invasion duct carcinoma	III	na	2/12	na	++
T6	<i>In-situ</i> and invasion duct carcinoma	III	III	7/18	+	++
T7	Invasive carcinoma, ductal type	III	III	0/13	na	-
T8	Invasive ductal carcinoma	II/III	II/III	na	-	-/+
T9	<i>In-situ</i> and invasive lobular carcinoma	II/III	II/III	7/16	+	+
T10	Invasive ductal carcinoma	III	III	5/18	na	+

<sup>a</sup> na, the information was not available; ER, estrogen receptor.




Fig. 3. Detection of SNCG mRNA and GAPDH mRNA in primary breast tumors and in matched normal breast tissue adjacent to tumors. RNA was isolated from 10 pairs of primary breast tissues; *T*, tumor tissue; *N*, normal breast adjacent to tumor. The PCR products were visualized on 1.5% agarose gels stained with ethidium bromide (*top panel*). The intensity of PCR product was scanned by Bio-Rad Fluoro-S MultiImager system and quantified by the program of Quantity One. The relative SNCG mRNA levels are presented as the ratio of SNCG mRNA:GAPDH mRNA. SNCG-positive cell line T47D was used in this experiment as a positive control. The data shown are representative of two to three separate RT-PCRs.

**Comparison of SNCG mRNA Expression and the Methylation Status of Exon 1 in Normal Breast Tissues with Invasive Breast Carcinomas.** It is possible that SNCG mRNA detected in the tumor-adjacent normal tissues was produced by infiltrated tumor cells instead of normal cells. Alternatively, the genetic background of non-cancerous tissue adjacent to the tumor cells has been changed, which could activate SNCG expression. We evaluated these possibilities by an examination of SNCG expression in 10 invasive tumors and in 6 normal breast tissues obtained from reduction mammoplasty of healthy individuals. RT-PCR analysis showed that of 10 tumor tissues, 8 displayed high expression of SNCG (Fig. 4A, *left panel*). In contrast, under the same conditions, RT-PCR did not detect SNCG expression in normal samples (Fig. 4A, *right panel*). The bisulfite genomic sequencing was done for five tumors and the results showed that all of the tumor samples contained mostly unmethylated *SNCG* gene, whereas the normal breast tissues contained methylated as well as unmethylated *SNCG* gene. The percentage methylation for normal breast and tumor samples is presented in Fig. 4B, and the difference in methylation was found to be statistically highly significant ( $P \leq 0.003$ ). Because the majority of genetic materials from normal breast tissue were derived from fat cells and fibroblasts, and only a small portion was actually from the epithelium, it is possible that the unmethylated allele belonged to other cell types.

We further extended our study to organoids. They were epithelial clumps obtained by digestion of normal breast tissue from one donor with collagenase and hyaluronidase at 37°C for 24–72 h. Fig. 5 showed the results of RT-PCR from the organoids before and after extensive cell culture to become finite HMECs. Whereas a very low level of SNCG mRNA was detected in the organoids in which epithelial cells were incubated in culture medium containing growth factors for only 24–72 h, a high level of SNCG mRNA was shown in the matching HMECs. Sequencing results showed that the organoids contained mostly methylated clones (75%) but the finite life span HMECs were completely unmethylated. These data combined with Fig. 1C suggest that SNCG is not expressed *in vivo* in normal

mammary epithelial cells, however, during the initial selection and culturing *in vitro*, the *SNCG* gene expression is induced through demethylation by growth factors present in the culture medium. SNCG expression may stimulate these primary cultures of cells to proliferate.

To further study that SNCG expression, controlled by demethylation, contributes to the cell proliferation, a normal mammary epithelial cell line HMEC-184 was treated with cytokine OM, which has been previously shown to inhibit the proliferation of HMECs (31). Cells were treated with OM at a concentration of 50 ng/ml for the indicated intervals of time, and cell proliferation was determined by [<sup>3</sup>H]thymidine incorporation assay. Fig. 6A shows that OM treatment led to 30% inhibition of cell growth after 1 day of treatment, whereas up to 60% of inhibition was observed after 3 days of treatment. RT-PCR analysis (Fig. 6B) showed that levels of SNCG expression in OM-treated cells was concomitantly reduced by 70% as compared with control. With bisulfite genomic sequencing, four of six clones were found to be methylated in OM-treated cells, whereas all five of the clones sequenced from the untreated cells were unmethylated.


Table 3. Bisulfite sequencing of cloned PCR products from breast tumor specimens

DNA was isolated from five pairs of primary breast tissues in which T represents tumor tissue and N represents normal breast tissue adjacent to tumor. Genomic bisulfite sequencing of the exon 1 region of *SNCG* was performed as described in the "Materials and Methods" section. Four to eight clones from each tissue sample were sequenced. The expression of SNCG mRNA was determined and described in Fig. 3.

Breast tissue samples	Total no. of clones sequenced	Exon 1 methylated	Exon 1 unmethylated	SNCG RT-PCR
N1	8	0	8	–
T1	8	1	7	++
N5	9	0	9	–
T5	7	1	6	++
N6	8	0	8	+
T6	8	1	7	+
N7	5	5	0	–
T7	6	4	2	–
N8	4	4	0	–
T8	8	6	2	-/+

Fig. 4. RT-PCR analysis of *SNCG* mRNA expression in breast tissue samples from healthy individuals and from patients with advanced breast carcinomas. **A**, six normal breast tissues *NA–NF* (right panel) were obtained from healthy donors after mammoplasty, and RNA was isolated from 300–400 mg of tissue per sample. RNA from 10 tumor tissues of advanced breast carcinomas *TA–TJ* (left panel) was also isolated. RT-PCR to detect *SNCG* and *GAPDH* mRNA was conducted. RNA of T47D cells was used as a positive control. **B**, DNA was isolated from six normal breast tissues (*NA–NF*) and five tumors (*TA, TC, TD, TF, TJ*). Genomic bisulfite sequencing of the exon 1 region of *SNCG* was performed for 6–8 clones per sample as described in the “Materials and Methods” section. The bar diagram, the percentage of methylated clones. The difference in the degree of methylation between normal samples and tumor samples was evaluated using two-tailed Student’s *t* test. Statistically significant difference ( $P = 0.003$ ) between normal and tumor samples was reached.

### A: RT-PCR



### B: Bisulfite Sequencing





Fig. 5. Expression of *SNCG* in organoid before and after culturing. RNA and DNA were isolated from organoids (240L) obtained from normal breast tissue of one donor after mammoplasty (Lane 1) and the matching HMECs that were developed from the same organoids after continuous culturing (Lane 2). RT-PCR to detect *SNCG* and *GAPDH* mRNA was conducted as described earlier. The bar diagram (bottom panel), the percentage of unmethylated clones after genomic sulfite sequencing.

To directly examine the relationship between *SNCG* expression and cellular proliferation, *SNCG* was stably transfected into MCF-7 cells, and pool population was selected for both mock- and *SNCG*-transfected cells. Western blot detected an abundant amount of *SNCG* protein in MCF7-*SNCG* transfectants (Fig. 7A). The proliferation rate of MCF7-*SNCG* was compared with mock-transfected MCF-7 cells by using Cyquant cell proliferation assay kit. Fig. 7B shows that *SNCG*-transfected cells proliferate faster than mock-transfected cells, and a >2-fold increase in cell proliferation was observed after 5 days. Cell cycle analysis (Fig. 7B, inset) showed that *SNCG*-transfected cells have more cells in S phase ( $33.11 + 3.2$  in *SNCG*-transfected cells compared with  $22.4 + 2.3$  in mock-transfected cells) and less in G<sub>2</sub>-M ( $15.06 + 2.8$  compared with mock-transfected cells ( $22.22 + 1.5$ )). Overall, these data suggest that *SNCG* is a stimulating factor for cell proliferation; the *SNCG* expression is correlated with demethylation of the exon 1 and that the inhibition of cell growth leads to an increased DNA methylation at the CpG island of the *SNCG* gene, resulting in reduced expression.

**Examination of *SNCG* mRNA Expression in Malignant and Normal Ovarian Epithelium-derived Cell Lines.** To determine whether demethylation of exon 1 is also a causal factor for *SNCG* expression in ovarian cancer cells, the experiments of RT-PCR and *in vivo* genomic sequencing were conducted in five ovarian tumor-derived cell lines and five normal ovarian epithelium-derived cell lines (HIOs). The results of RT-PCR are presented in Fig. 8, upper panel, and the summarized sequencing data are shown in Fig. 9. Among the five cancer cell lines, OVCAR3 and OVCAR5 expressed high levels of *SNCG* mRNA, and these cells contained fully demethylated exon 1, whereas A2780 expressed a moderate level of *SNCG* mRNA, and exon 1 in these cells was partially methylated. In




Fig. 6. Regulation of cell proliferation and *SNCG* mRNA expression and DNA methylation in HMEC-184 by OM. **A**,  $1.2 \times 10^4$  cells were seeded in 24-well plate and treated with 50 ng/ml for 1 and 3 days. Cells were then pulsed with [<sup>3</sup>H]thymidine for 16 h. The amount of radioactivity incorporated was determined by trichloroacetic acid precipitation. **B**, mRNA expression and DNA methylation of *SNCG* in HMEC-184 by RT-PCR analysis and DNA bisulfite sequencing. Equal numbers of cells were seeded in 100-mm dishes for control and OM treatment of 3 days. The cells were then harvested for RNA and DNA isolation. The bar diagram (bottom panel), the percentage of unmethylated clones after genomic sulfite sequencing.




Fig. 7. Cell proliferation assay and cell cycle distribution of DNA in mock- and SNCG-transfected cells. A, MCF-7 was transfected with the pCIneo vector or with pCIneo-SNCG, and the pool populations were selected with 300  $\mu$ g/ml G418. SNCG protein expression in the mock- and SNCG-transfected pool population of MCF-7 was examined by Western blot by using 20  $\mu$ g of protein of total cell lysate. B, 1000 cells were seeded per well in black 96-well plates for each cell type and harvested at indicated intervals of time. The total DNA content was estimated using fluorescent dye as described in "Materials and Methods." The proliferation rate is expressed as the fold of DNA content in day 1 of each cell population. The data presented are derived from three separate experiments in which quadruplicate wells were used in each condition. The proliferation assay was also carried out in medium containing a different amount of FBS, and the proliferation rates of MCF7-SNCG cells were consistently higher than MCF7-neo cells in all of the assays. *Inset*, for cell cycle analysis,  $2 \times 10^5$  cells were seeded in 100-mm dishes in RPMI containing 10% media. Next day, the cells were washed with PBS, and RPMI containing 0.5% of medium was added to the cells. After 48 h, the cells were harvested and analyzed by flow cytometry.

contrast, OVCAR4 and OVCAR8 did not express SNCG mRNA at all, and all of the 15 CpG sites of the CpG island in these two cell lines were completely methylated. Thus, SNCG expression appears to correlate very well with the demethylation of *SNCG* gene in ovarian cancer cell lines. Interestingly, the methylation pattern in ovarian cancer cells is different from that in breast cancer cells. The specific methylation patterns of ovarian cancer cell lines and breast cancer cell lines are presented in Table 4. Among the five normal HIO cell lines, SNCG mRNA was detected only in HIO-107 cells. Within eight clones of HIO-107 that were sequenced, four clones were completely methylated at every CpG site of CpG island, whereas the four other clones were nearly unmethylated. Other HIO lines showed no expression of SNCG mRNA, although all four of the cell lines displayed demethylation of the CpG island to a different extent. Thus, these data suggest that in normal ovarian epithelium-derived cell lines, besides DNA methylation, there are other factors that repress SNCG expression. Because all of the CpG sites in the CpG island of SNCG in ovarian cancer cells were methylated in SNCG-negative cells and unmethylated in SNCG-positive cells, it is possible to determine the methylation status by using a MSP assay. To explore this possibility, the bisulfite-modified genomic DNAs were amplified with the methylation-specific primers SNCG-M1F or SNCG-M2R, or the primers corresponding to unmethylated sequence, SNCG-U1CF and SNCG-U2R (Table 1). The *bottom panel* of Fig. 8 shows that a strong band of 102 bp (*SNCG-M*), corresponding to methylated sequence of exon 1 (-139 to -37), was amplified with the methylated primers from SNCG-negative OVCAR4 and OVCAR8 cells, but this band was not amplified from SNCG-positive OVCAR3 and OVCAR5 cells. In

contrast to the methylated primers, the same region was specifically amplified using unmethylated primers from OVCAR3 and OVCAR5 but was not amplified from OVCAR4 and OVCAR8. MSP detected both methylated and unmethylated alleles from A2780. Thus, the MSP produced similar results as the direct sequencing. Likewise, the results of MSP of five HIO cell lines agreed to a large degree with the sequencing data and showed that HIO-107 and HIO-108 contained unmethylated and methylated alleles and HIO-103 and -105 contained mostly unmethylated alleles, whereas HIO-135 contained mainly methylated *SNCG* gene. These data suggest that MSP can reliably




Fig. 8. Detection of SNCG mRNA in ovarian cancer and normal ovarian epithelium-derived (HIO) cell lines by RT-PCR analysis and the methylation status of exon 1 by MSP. A, the ovarian cancer and HIO cells were analyzed for SNCG mRNA and  $\beta$ -actin mRNA. B, MSP was used to assess the methylation status of SNCG CpG islands in each cell line. Bisulfite-modified genomic DNA was used as template to amplify exon 1 region -139 to -37. The PCR reactions with primers to detect methylated DNA and unmethylated DNA were performed separately. *SNCG-M*, methylated primers; *SNCG-U*, unmethylated primers; *SNCG-wt*, primers corresponding to the wild-type sequence of unmodified DNA. The unmodified genomic DNA was amplified with primers corresponding to the wild-type sequence as a positive control for the quality of DNA.




Fig. 9. Methylation status of CpG islands in SNCG exon 1 region in various ovarian cancer and HIO cell lines. CpG positions are indicated relative to the translation start codon, and *each circle* in the figure represents a single CpG site. For each cell line, the percentage methylation at a single CpG site is calculated from the sequencing results of 6-8 independent clones. ●, 100% methylation; ○, 0% methylation.

Table 4 Comparison of methylation patterns of breast epithelium-derived cells with ovarian epithelium-derived cell lines

	CpG position														
	1/-168	2/-138	3/-122	4/-119	5/-103	6/-93	7/-88	8/-78	9/-62	10/-55	11/-37	12/+30	13/+42	14/+53	15/+80
MDA-MB468	-	+	-	-	+	-	+	-	-	+	+	+	+	+	+
	-	+	-	-	+	-	+	-	+	+	+	+	+	+	+
	-	+	-	-	+	-	+	-	+	+	+	+	+	+	+
	-	+	-	-	+	-	+	-	+	+	+	+	+	+	+
	0	100	0	0	100	0	100	0	66.7	100	100	100	100	100	100% methylation
MCF10A	-	+	-	-	+	-	+	-	-	+	+	+	+	+	+
	-	+	-	-	+	-	+	-	-	+	+	+	+	+	+
	-	+	-	-	+	-	+	-	-	+	+	+	+	+	+
	-	+	-	-	+	-	+	-	-	+	+	+	+	+	+
	-	+	-	-	+	-	+	-	-	+	+	+	+	+	+
	-	+	-	-	+	-	+	-	-	+	+	+	+	+	+
	0	100	0	0	100	0	100	0	0	100	100	100	100	100	100% methylation
OVCAR-4	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	-	+	+	+	-	+	-	+	+	+	+	+	+	+	+
	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	-	+	-	+	+	-	-	+	-	-	+	-	+
	50	100	75	100	75	100	87.5	87.5	87.5	100	87.5	87.5	100	87.5	100% methylation
OVCAR-8	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
	100	100	75	87.5	100	100	100	100	100	100	100	100	100	100	100% methylation

distinguish the unmethylated *SNCG* from the methylated gene in ovarian cancer cells.

**Reexpression of *SNCG* by 5-Aza-C Treatment.** If the transcriptional silencing of *SNCG* can be attributed to the methylation of exon 1, then demethylating the gene with 5-Aza-C should lead to expression of *SNCG* in both breast cancer and ovarian cancer cells. To test this, we chose two *SNCG*-negative breast cancer cell lines (MDA-MB435 and MCF-7), two *SNCG*-negative ovarian cancer cell lines (OVCAR4 and OVCAR8), and one *SNCG*-negative HIO cell line (HIO-135). All of these cell lines contain methylated *SNCG* gene. Cells were exposed to different concentrations of 5-Aza-C for 4–6 days, and the medium and drug were replaced daily. Fig. 10A shows that, in breast cancer cells, *SNCG* mRNA expression was induced by low doses of 5-Aza-C (0.6  $\mu$ M for MCF-7 and 1  $\mu$ M for MDA-MB435), and its level was increased by higher concentrations of 5-Aza-C in a dose-dependent manner. In the two ovarian tumor lines, higher doses (10  $\mu$ M) of 5-Aza-C were required to induce *SNCG* expression as compared with 1  $\mu$ M for the HIO-135 cells (Fig. 10B). To confirm that reactivation of *SNCG* expression by 5-aza-C was the result of the demethylation of the exon 1, we isolated DNA from OVCAR4 and OVCAR8, which had been treated with a 10- $\mu$ M concentration of 5-aza-C, and performed bisulfite sequencing. As expected, the CpG islands in these ovarian tumor cells became unmethylated (data not shown). In contrast to *SNCG*-negative cell lines, 5-aza-C treatment of OVCAR3 and OVCAR5 did not further increase the level of *SNCG* expression. Collectively, these data clearly demonstrate that reactivation of *SNCG* expression by 5-Aza-C was the direct effect of demethylation of exon 1 and was not a secondary effect caused by other factors the expression of which were changed by the treatment.

**DISCUSSION**

The onset of cancer is associated with the silencing of the tumor suppressor genes and activation of proto-oncogenes. Previous studies have suggested that *SNCG* could function as an oncogene in breast cancer cells. It has been demonstrated that exogenous expression of *SNCG* in breast cancer cells (MDA-MB435) led to a significant




Fig. 10. Re-expression of *SNCG* mRNA after 5-Aza-dC treatment in breast and ovarian cancer cell lines. Breast cancer cell lines MCF-7 and MDA-MB 435 were treated with indicated doses of 5-Aza-dC for 4 days (A) and ovarian cancer cell lines and HIO 135 line were treated with 5-Aza-dC for 6 days (B). RNA from each cell line was isolated at the end of treatment, and the expressions of *SNCG* mRNA and GAPDH or  $\beta$ -actin mRNA were determined by RT-PCR.

increase in cell motility and invasiveness in cell culture and to a profound augmentation of metastasis in nude mice (24). Furthermore, exogenous expression of SNCG in MCF-7 cells significantly stimulated the growth of MCF-7 cells under anchorage-dependent (Fig. 7) and anchorage-independent conditions (33), whereas blocking SNCG expression with SNCG antisense mRNA markedly reduced the colony formation of T47D cells (25). Although previous studies by our group and others have shown that SNCG was abnormally expressed in advanced-stage breast carcinoma and ovarian carcinoma and that it is likely to be important in the pathogenesis of these neoplastic diseases, the mechanism(s) for its aberrant expression was unclear. In this report, we extensively examined the relationship between demethylation or hypomethylation of SNCG CpG island, and the expression of this candidate oncogene in breast cancer and ovarian cancer under both *in vitro* and *in vivo* conditions. From our present study, four important findings emerged.

First, in breast cancer cell lines, SNCG expression correlates with complete demethylation of the exon 1 region. By contrast, three of four SNCG-negative cell lines showed specific methylation at the CpG sites 2, 5, 7, and 10–15, suggesting that methylation at these sites is sufficient to block the expression of this gene in cell culture. More importantly, these same CpG sites were found methylated in primary breast tumor tissues and in MCF-10A, a cell line that originated from normal mammary epithelium. Thus, these data argue that, in normal mammary epithelium, SNCG is methylated at the specific CpG sites, resulting in blocking of transcription.

Semiquantitative RT-PCR, a highly sensitive detection method, failed to identify SNCG expression in six of six normal breast tissues from healthy women without cancer. This result provided new evidence to support original findings that SNCG expression was confined to malignant mammary epithelial cells. *In vivo* genomic sequencing, however, detected both methylated and unmethylated SNCG gene from the same normal breast tissue samples. We tentatively interpret this discrepancy thus: the unmethylated genes could be derived from other cell types such as fat cells, fibroblasts, or mononuclear leukocytes, and the lack of expression in these cells could be controlled by other mechanisms. However, our results cannot exclude the possibility that in normal mammary epithelium, SNCG is partially methylated and that partial methylation is sufficient to block its expression. Additional studies to examine SNCG expression and methylation in nonepithelial cell types of breast tissue will be needed to resolve this discrepancy. The unmethylated exon 1 in normal tissues adjacent to tumors suggests that demethylation may precede expression. A similar observation has been reported in benign and malignant colon neoplasms (9). Although the benign tumors do not express HGH,  $\alpha$  and  $\gamma$  globin genes were hypomethylated in the promoter region of these genes just like malignant tissues, thereby suggesting that alteration in DNA methylation precedes malignancy.

The second important finding in this study is that DNA methylation also plays an important role in SNCG expression in ovarian cancer cells. Similar to breast cancer cells, an inverse relationship between exon 1 methylation and SNCG expression was found in various ovarian cancer and HIO cell lines. However, there are two characteristics that are unique and distinguish ovarian-derived epithelial cells from breast-derived epithelial cells. First, the 15 CpG sites in ovarian cancer cells were all methylated instead of being selectively methylated at the hot spots that were identified in breast cancer cells. Secondly, in ovarian cells, partial methylation permitted SNCG expression, albeit at a lower level, whereas SNCG expression could not be detected in breast cancer cells in which the exon 1 was partially and heterogeneously methylated. These differences suggest that, whereas partial methylation in the exon 1 is adequate to inhibit SNCG expression in breast cancer cells, complete methylation of the CpG island is

required for silencing SNCG in ovarian cancer cells. The third finding of this study is that SNCG is expressed in three primary HMEC lines (184, 048R, and 240L) that have limited life span and that the expression correlates with hypomethylation of the exon 1. By contrast, SNCG is not expressed in normal mammary epithelial cells *in vivo* nor in the established cell line MCF-10A, and is detected at a very low level in organoids before extensive culturing. These observations suggest that SNCG expression and demethylation of the exon 1 are regulated possibly by growth factors that are present in culture medium during the establishment of HMEC cell lines. Consequently, SNCG gene product further stimulates cell proliferation of the primary mammary epithelial cells that normally have low growth potential. Although this is a hypothetical scenario, there is some evidence to support this hypothesis. Celis *et al.* (34) have reported that a group of genes that were not expressed in the original bladder transitional carcinomas became expressed when the tumor tissues were incubated in culture medium for a very short time (1–2 days). Synuclein was found within this group. Future studies to clearly define the function of this protein in neoplasm will provide insight to understand the molecular mechanisms that control the methylation status of SNCG gene.

The last important finding is that we provided direct evidence to demonstrate a stimulating role of SNCG in the growth of breast cancer cells. Transfection of SNCG into MCF-7 cells resulted in an increased proliferation rate of cells. Conversely, we also demonstrated a correlation between reduced growth rate and decreased SNCG expression. Importantly, we showed the coordinated changes in cell growth, SNCG mRNA level, and methylation status of the exon 1 of SNCG gene. When the HMECs, which express high levels of SNCG, are arrested by OM or by serum starvation (data not shown), the SNCG levels decrease, and the exon 1 becomes hypermethylated. At the present, the normal cellular functions of SNCG are largely unknown. Future studies to clearly define the function of this protein in neurons as well as in neoplasm will provide insight to understand the molecular mechanisms that control the methylation status of SNCG gene.

Currently, in the cancer research field, DNA hypermethylation has received considerable attention, and DNA hypomethylation is studied inadequately. In fact, the original observation of altered DNA methylation in cancer was hypomethylation (16). A recent study of genome-wide screening for normally methylated human CpG islands has found a considerable number of genes containing methylated CpG islands. We believe that our studies provide a clearly defined example supporting the hypothesis that abnormal hypomethylation contributes to cancer formation.

## ACKNOWLEDGMENTS

We thank Dr. Martha R. Stampfer for her valuable suggestions on HMEC culturing, Dr. Zhong-Zong Pan for his helpful input, and the Tissue Bank and Biosample Repository Core Facility's (Fox Chase Cancer Center, Philadelphia, PA) staff members for providing tissue samples.

## REFERENCES

- Zheng, S., Chen, P., McMillan, A., Lafuente, A., Lafuente, M. J., Ballesta, A., Trias, M., and Wiencke, J. K. Correlations of partial and extensive methylation at the p14ARF locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. *Carcinogenesis (Lond.)*, 21: 2057–2064, 2000.
- Esteller, M., Sparks, A., Toyota, M., Sanchez-Cespedes, M., Capella, G., Peinado, M., Gonzalez, S., Tarafa, G., Sidransky, D., Meltzer, S., Baylin, S., and Herman, J. Analysis of adenomatous Polyposis coli promoter hypermethylation in human cancer. *Cancer Res.*, 60: 4366–4371, 2000.
- Jackson-Grusby, L., Beard, C., Possemato, R., Tudor, M., Fambrough, D., Csankovszki, G., Dausman, J., Lee, P., Wilson, C., Lander, E., and Jaenisch, R. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. *Nat. Genet.*, 27: 31–39, 2001.

4. Magdinier, F., and Wolffe, A. P. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. *Proc. Natl. Acad. Sci. USA*, *98*: 4990–4995, 2001.
5. Li, J., Cao, Y., Young, M. R., and Colburn, N. H. Induced expression of dominant-negative c-jun downregulates *NF $\kappa$ B* and *AP-1* target genes and suppress tumor phenotype in human keratinocytes. *Mol. Carcinog.*, *29*: 159–169, 2000.
6. Hattori, M., and Sakamoto, H. K. T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of *c-erbB-2* and *survivin* genes. *Cancer Lett.*, *169*: 155–164, 2001.
7. Kudo, S., and Fukuda, M. Tissue-specific transcriptional regulation of *human leuko-sialin (CD43)* gene is achieved by DNA methylation. *J. Biol. Chem.*, *270*: 13298–13302, 1995.
8. Feinberg, A. P., and Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their counterparts. *Nature (Lond.)*, *301*: 89–91, 1983.
9. Goetz, S. E., Vogelstein, B., Hamilton, S. R., and Feinberg, A. P. Hypomethylation of DNA from benign and malignant human colon neoplasms. *Science (Wash. DC)*, *228*: 187–190, 1985.
10. Fang, J., Zhu, S., Xiao, S., Jiang, S., Shi, Y., Chen, X., Zhou, X., and Qian, L. Studies on the hypomethylation of *c-myc*, *c-Ha-ras* oncogenes and histopathological changes in human gastric carcinoma. *J. Gastroenterol. Hepatol.*, *11*: 1079–1082, 1996.
11. Rosty, C., Ueki, T., Argani, P., Jansen, M., Yeo, C., Cameron, J., Hruban, R., and Goggins, M. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. *Am. J. Pathol.*, *60*: 45–50, 2002.
12. Cho, M., Uemura, H., Kim, S., Kawada, Y., Yoshida, K., Hirao, Y., Konishi, N., Saga, S., and Yoshikawa, K. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. *Br. J. Cancer*, *85*: 563–567, 2001.
13. Nakayama, M., Wada, M., Harada, T., Nagayama, J., Kusaba, H., Ohshima, K., Kozuru, M., Komatsu, H., Ueda, R., and Kuwano, M. Hypomethylation status of CpG sites at the promoter region and overexpression of the human *MDR1* gene in acute myeloid leukemias. *Blood*, *92*: 4296–4307, 1998.
14. Hanada, M., Delia, D., Aiello, A., Stadtmauer, E., and Reed, J. *BCL-2* gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. *Blood*, *82*: 1820–1828, 1993.
15. De Smet, C., De Backer, O., Faraoni, I., Lurquin, C., Brassuer, F., and Boon, T. The activation of human gene *MAGE-1* in tumor cells is correlated with genome-wide demethylation. *Proc. Natl. Acad. Sci. USA*, *93*: 7149–7153, 1996.
16. Strichman-Almashanu, L. Z., Lee, R. S., Onyango, P. O., Perlman, E., Flam, F., Frieman, M. B., and Feinberg, A. P. A genome wide screen for normally methylated human CpG islands that can identify novel imprinted genes. *Genome Res.*, *12*: 543–554, 2002.
17. Ueda, K., Fukushima, H., Masliah, E., Xia, Y., Iwai, A., Yoshimoto, M., Otero, D., Kondo, J., Ihara, Y., and Saitoh, T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Proc. Natl. Acad. Sci. USA*, *90*: 11282–11286, 1993.
18. Xia, Y., Rohan de Silva, H., Rosi, B., Yamaoka, L., Rimmler, J., Pericak-Vance, M., Roses, A., Chen, X., Masliah, E., DeTeresa, R., Iwai, A., Sundsmo, M., Thomas, R., Hofstetter, C., Gregory, E., Hansen, L., Katzman, R., Thal, L., and Saitoh, T. Genetic studies in Alzheimer's disease with a NACP/a-synuclein polymorphism. *Ann. Neurol.*, *40*: 207–215, 1996.
19. Jakes, R., Spillantini, M., and Goedert, M. Identification of two distinct synucleins from human brain. *FEBS Lett.*, *345*: 27–34, 1994.
20. Lavedan, C., Leroy, E., Dehejia, A., Buchholtz, S., Dutra, A., Nussbaum, R., and Polymeropoulos, M. Identification, localization and characterization of the human *a-synuclein* gene. *Hum. Genet.*, *103*: 106–112, 1998.
21. Ninkina, N., Alimova-Kost, M., Paterson, J., Delaney, L., Cohen, B., Imreh, S., Gnuchev, N., Davies, A., and Buchman, V. Organization, expression and polymorphism of the human *persyn* gene. *Hum. Mol. Genet.*, *7*: 1417–1424, 1998.
22. Ji, H., Liu, Y., Jia, T., Wang, M., Liu, J., Xiao, G., Joseph, B., Rosen, C., and Shi, Y. Identification of a breast cancer-specific gene, *BCSG1*, by direct differential cDNA sequencing. *Cancer Res.*, *57*: 759–764, 1997.
23. Bruening, W., Giasson, B., Klein-Szanto, J., Lee, V., Trojanowski, J., and Godwin, A. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. *Cancer (Phila.)*, *88*: 2154–2163, 2000.
24. Jia, T., Liu, Y., Liu, J., and Shi, Y. Stimulation of breast cancer invasion and metastasis by breast cancer-specific synuclein (SNCG). *Cancer Res.*, *59*: 742–747, 1999.
25. Lu, A., Zhang, F., Gupta, A., and Liu, J. Blockade of AP1 transactivation abrogated the abnormal expression of the *breast cancer specific gene 1* in breast cancer cells. *J. Biol. Chem.*, *277*: 31364–72, 2002.
26. Lu, A., Gupta, A., Li, C., Ahlborn, T. E., Ma, Y., Shi, E. Y., and Liu, J. Molecular mechanisms for aberrant expression of the *human breast cancer specific gene 1* in breast cancer cells: control of transcription by DNA methylation and intronic sequences. *Oncogene*, *20*: 5173–5185, 2001.
27. Godwin, A., Meister, A., O'Dwyer, P., Huang, C., Hamilton, T., and Anderson, M. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. *Proc. Natl. Acad. Sci. USA*, *89*: 3070–3074, 1992.
28. Auersperg, N., Maines-Bndiera, S., Booth, J. H., Lynch, H. T., Godwin, A. K., and Hamilton, T. C. Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. *Am. J. Obst. Gyn.*, *173*: 558–565, 1995.
29. Grobelny, J., Godwin, A., and Broccoli, D. ALT-Associated PML Bodies (AA-PBs) are dynamic structures that accumulate in G<sub>2</sub>/M phase of the cell cycle. *J. Cell Sci.*, *113*: 4477–4485, 2000.
30. Liu, J., Li, C., Ahlborn, T. E., Spence, M. J., Meng, L., and Boxer, L. M. The expression of *p53* tumor suppressor gene in breast cancer cells is down-regulated by cytokine oncostatin M. *Cell Growth Differ.*, *5*: 15–18, 1999.
31. Liu, J., Hadjokas, N., Mosley, B., Estrov, Z., Spence, M. J., and Vestal, R. E. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant epithelial cells. *Cytokine*, *10*: 295–302, 1998.
32. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, D., and Kohn, K. W. Role of *p53* tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. *Cancer Res.*, *53*: 4776–4780, 1993.
33. Liu, J., Spence, M. J., Zhang, Y. L., Jiang, Y., Liu, Y., and Shi, Y. Transcriptional suppression of synuclein  $\gamma$  (SNCG) expression in human breast cancer cells by the growth inhibitory cytokine oncostatin M. *Breast Cancer Res. Treat.*, *62*: 99–107, 2000.
34. Celis, A., Rasmussen, H., Celis, P., Basse, B., Lauridsen, J., Ratz, G., Hein, B., Ostergaard, M., Wolf, H., Orntoft, T., and Celis, J. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. *Electrophoresis*, *20*: 355–361, 1999.

# Announcements

## MEETING OF THE RADIATION RESEARCH SOCIETY

The annual meeting of the Radiation Research Society will be held at the State University of Iowa, Iowa City, on June 22-24, 1953. The Society will be the guest of the University, and all meetings will be held on the campus. The program will consist of: (1) Two symposia, one on "The Effects of Radiation on Aqueous Solutions," which includes the following speakers: E. S. G. Barron, Edwin J. Hart, Warren Garrison, J. L. Magee, and A. O. Allen. The second is "Physical Measurements for Radiobiology" and companion talks by Ugo Fano, Burton J. Moyer, G. Failla, L. D. Marinelli, and Payne

S. Harris. (2) On Monday night, June 22, a lecture by Dr. L. W. Alvarez on meson physics has been tentatively scheduled. On Tuesday night, June 23, Dr. L. H. Gray of the Hammersmith Hospital, London, will speak on a topic to be announced. Dr. Gray's lecture is sponsored by the Iowa Branch of the American Cancer Society. Those desiring to report original research in radiation effects, or interested in attending or desiring additional information, please contact the Secretary of the Society, Dr. A. Edelman, Biology Department, Brookhaven National Laboratory, Upton, L.I., New York.

## ERRATUM

The following correction should be made in the article by Beck and Valentine, "The Aerobic Carbohydrate Metabolism of Leukocytes in Health and Leukemia. I. Glycolysis and Respiration," November, 1952, page 821; substitute for the last paragraph:

The data in Table 3 permit several interesting calculations. If one compares the amount of glucose actually disappearing with the sum of the amount equivalent to lactic acid produced plus that equivalent to O<sub>2</sub> consumption, it is seen that the amount of glucose "cleavage products" exceeds the amount of glucose utilized by 12 per cent in N and 27 per cent in CML and is exceeded

by the glucose utilized by 16 per cent in CLL. If the assumption is made that, *in this respect*, the myeloid and lymphoid cells of leukemia are similar to those of normal blood, it may be that the computed normal figure represents a summation of the myeloid (M) and lymphoid (L) cells that make up the normal leukocyte population. Thus, if M = +0.27 and L = -0.16 and the normal differential is 65 per cent M and 35 per cent L, then

$$0.65 (+0.27) + 0.35 (-0.16) = +0.12 ,$$

a figure identical to the observed +0.12 for normal leukocytes.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Hypomethylation of the *Synuclein* $\gamma$ Gene CpG Island Promotes Its Aberrant Expression in Breast Carcinoma and Ovarian Carcinoma

Anu Gupta, Andrew K. Godwin, Lisa Vanderveer, et al.

*Cancer Res* 2003;63:664-673.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/63/3/664>

**Cited articles** This article cites 33 articles, 14 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/63/3/664.full#ref-list-1>

**Citing articles** This article has been cited by 14 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/63/3/664.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/63/3/664>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.